Zymeworks Inc. (ZYME)
Nasdaq · Healthcare · Biotechnology
$26.21+4.21%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.9B
- Forward P/E
- 30.1
- 52-week range
- $16.00 – $31.34
- 52-week change
- +52.42%
- EPS (trailing)
- −$2.02
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $106M (+38.88%)
- Net income
- −$81.1M
- Operating margin
- −87.3%
- Diluted EPS
- −$1.08
- Free cash flow
- −$34.5M
From the company’s annual report on SEC EDGAR.
About Zymeworks Inc.
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC…
Headquarters: Middletown, United States · 231 employees · zymeworks.com